Azelaic Acid

Azelaic Acid

SCHEMBL3338900

NCCCC[C@H](N)C(=O)O.O=C(O)CCCCCCCC(=O)O

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Azelaic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.77
LMNA P02545 2/20 0.65
THRB P10828 2/20 0.65
KMT2A Q03164 2/20 0.65
ALDH1A1 P00352 2/20 0.65
MEN1 O00255 1/20 0.65
PLG P00747 1/20 0.65
ALOX15 P16050 1/20 0.65
SLC6A2 P23975 1/20 0.65
RECQL P46063 1/20 0.65
SLC6A3 Q01959 1/20 0.65
CYP2D6 P10635 1/20 0.61
NFKB1 P19838 1/20 0.61
BLM P54132 2/20 0.59
NPSR1 Q6W5P4 2/20 0.59
BHMT Q93088 4/20 0.59
CYP1A2 P05177 2/20 0.57
GRM8 O00222 1/20 0.57
GRM6 O15303 1/20 0.57
GRIN2D O15399 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lysine SCHEMBL8594448 1.00 GSR (0.77) GSRLMNATHRBKMT2AALDH1A1
Lysine SCHEMBL14343193 1.00 GSR (0.77) GSRLMNATHRBKMT2AALDH1A1
Octanedioate SCHEMBL18496728 1.00 GSR (0.77) GSRLMNATHRBKMT2AALDH1A1
Pimelic Acid SCHEMBL19031711 1.00 GSR (0.77) GSRLMNATHRBKMT2AALDH1A1
Pimelic Acid SCHEMBL19031710 1.00 GSR (0.77) GSRLMNATHRBKMT2AALDH1A1
Azelaic Acid SCHEMBL3338898 1.00 GSR (0.77) GSRLMNATHRBKMT2AALDH1A1
Lysine SCHEMBL19210217 1.00 GSR (0.77) GSRLMNATHRBKMT2AALDH1A1
Octanedioate SCHEMBL18496726 1.00 GSR (0.77) GSRLMNATHRBKMT2AALDH1A1
Lysine SCHEMBL22411244 1.00 GSR (0.77) GSRLMNATHRBKMT2AALDH1A1
Sebacic Acid SCHEMBL5379246 1.00 GSR (0.77) GSRLMNATHRBKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115708783-A Formula of liquid crystal emulsifier composition and application of liquid crystal emulsifier composition in cosmetics 美特瑞生物科技(上海)有限公司 2023-02-24 CN claimed
US-20060159714-A1 Use of an antioxidant in a dermatological and/or cosmetic composition THOREL JEAN-NOEL 2006-07-20 US claimed
WO-2026100897-A1 LYSINE DECARBOXYLASE DERIVED FROM PANTOEA ALHAGI AND METHOD FOR PRODUCING CADAVERINE USING MICROORGANISM COMPRISING SAME 씨제이제일제당 (주) 2026-05-15 WO disclosed
US-20250275904-A1 ANTI-SUN COSMETIC COMPOSITION CONTAINING MYCOSPORINE-LIKE AMINO ACIDS Thorel, Jean-Noël (FR) 2025-09-04 US disclosed
US-20250049685-A1 COLLAGEN LOTION FORMULATIONS AND METHODS OF USE THEREOF Wellbeam Consumer Health Intermediate, LLC (US) 2025-02-13 US disclosed
US-20250049684-A1 COLLAGEN CREAM FORMULATIONS AND METHODS OF USE THEREOF Wellbeam Consumer Health Intermediate, LLC (US) 2025-02-13 US disclosed
US-20250049686-A1 COLLAGEN SERUM FORMULATIONS AND METHODS OF USE THEREOF Wellbeam Consumer Health Intermediate, LLC (US) 2025-02-13 US disclosed
EP-4389214-A2 USE OF TRIMETHOXYBENZYL ACETYLSINAPATE, ADVANTAGEOUSLY IN COMBINATION WITH AT LEAST ONE SUNSCREEN, FOR PROTECTING THE SKIN Thorel, Jean-Noël (FR) 2024-06-26 EP disclosed
EP-4366686-A1 ANTI-SUN COSMETIC COMPOSITION CONTAINING MYCOSPORINE-LIKE AMINO ACIDS NAOS Institute of Life Science (FR) 2024-05-15 EP disclosed
EP-3466419-B1 USE OF TRIMETHOXYBENZYL ACETYLSINAPATE, ADVANTAGEOUSLY IN COMBINATION WITH AT LEAST ONE SUNSCREEN, FOR PROTECTING THE SKIN THOREL JEAN NOEL (FR) 2024-05-08 EP disclosed
US-20240041727-A1 GLYCOSYLATED BACTERIORUBERINS AND INDUSTRIAL APPLICATIONS THEREOF NAOS INSTITUTE OF LIFE SCIENCE (FR) 2024-02-08 US disclosed
CN-1819824-B Use of antioxidants in dermatological and/or cosmetic compositions JEAN-NOEL THOREL 2010-05-12 CN disclosed
EP-2120846-A2 USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS BASF SE (DE) 2009-11-25 EP disclosed
WO-2008107347-A2 USE OF AMINES AND AMIDES FOR THE STABILIZATION OF ORGANIC MICRONIZED UV ABSORBERS BASF SE (CH) 2008-09-12 WO disclosed
CN-1819824-A Use of antioxidants in dermatological and/or cosmetic compositions JEAN-NOEL THOREL (FR) 2006-08-16 CN disclosed
US-20060159714-A1 Use of an antioxidant in a dermatological and/or cosmetic composition THOREL JEAN-NOEL 2006-07-20 US disclosed
US-20060159714-A1 Use of an antioxidant in a dermatological and/or cosmetic composition THOREL JEAN-NOEL 2006-07-20 US disclosed
EP-1641476-A2 USE OF AN ANTIOXIDANT IN A DERMATOLOGICAL AND/OR COSMETIC COMPOSITION Thorel, Jean-Noel (FR) 2006-04-05 EP disclosed
WO-2005004891-A3 USE OF AN ANTIOXIDANT IN A DERMATOLOGICAL AND/OR COSMETIC COMPOSITION THOREL JEAN-NOEL (FR) 2005-06-09 WO disclosed
WO-2005004891-A2 USE OF AN ANTIOXIDANT IN A DERMATOLOGICAL AND/OR COSMETIC COMPOSITION THOREL JEAN-NOEL (FR) 2005-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275904-A1 ANTI-SUN COSMETIC COMPOSITION CONTAINING MYCOSPORINE-LIKE AMINO ACIDS CUTA, MYC, XPA GSR 3946/4885LMNA 1602/4885THRB 4524/4885
US-20240041727-A1 GLYCOSYLATED BACTERIORUBERINS AND INDUSTRIAL APPLICATIONS THEREOF BPGM, DDOST, UGGT1 GSR 2389/4885LMNA 4116/4885THRB 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.